Navigation Links
Genetic variation increases risk of metabolic side effects in children on some antipsychotics
Date:1/24/2012

Researchers have found a genetic variation predisposing children to six-times greater risk of developing metabolic syndrome when taking second-generation anti-psychotic medications. Metabolic syndrome is a cluster of conditions that are risk factors for cardiovascular disease. The study showed a close association with two conditions in particular: high blood pressure and elevated fasting blood sugar levels, which is a precursor to diabetes. The research is published today in the medical research journal Translational Psychiatry.

"This is the first report of an underlying biological factor predisposing children to complications associated with second-generation anti-psychotic medication use," says Dr Dina Panagiotopoulos, study co-author, clinician scientist at the Child & Family Research Institute (CFRI), pediatric endocrinologist at BC Children's Hospital, and assistant professor, Department of Pediatrics, University of British Columbia (UBC).

"It's concerning because these children take medications to treat a chronic disease mental illness and then develop risk factors for a second chronic disease," says Dr. Angela Devlin, study co-author, CFRI scientist and assistant professor in the UBC Department of Pediatrics.

Second-generation anti-psychotics are prescribed to approximately 5500 children and youth in British Columbia for psychotic disorders, mood and anxiety disorders, attention deficit hyperactivity disorder, autism spectrum disorders, adjustment disorders and substance abuse. Of these medications, the two most commonly prescribed in B.C. are quetiapine (Seroquel) and risperidone (Risperdal).

For the study, researchers assessed 209 children who were inpatients between April 2008 and June 2011 at the Child & Adolescent Psychiatry Department at BC Children's Hospital, an agency of the Provincial Health Services Authority. Their average age was 13 years, and 105 of the children were treated with second-generation anti-psychotics while 112 did not use these drugs. DNA analysis showed that eight per cent of children from both groups had a genetic variation called C677T on the MTHFR gene. Children with the MTHFR C677T variant who used these medications were six-times more likely to have metabolic syndrome.

The researchers targeted the MTHFR C677T variant because it is known to be associated with metabolic syndrome in adults who have schizophrenia, and with cardiovascular disease in adults who don't have psychiatric illness.

Dr. Devlin and Dr. Panagiotopoulos say their discovery is an important step to preventing and managing metabolic complications associated with second-generation antipsychotic medications. It is critical to reduce these risks in childhood because adults with mental illness have a 19 per cent increased mortality rate that is largely due to cardiovascular disease risk.

The MTHFR gene is involved in metabolizing the B-vitamin folate.

"We now plan to assess B vitamin status and dietary intake in children who take these medications to gain a better understanding of this association," says Dr. Panagiotopoulos.


'/>"/>
Contact: Jennifer Kohm
jkohm@cfri.ca
604-875-2401
Child & Family Research Institute
Source:Eurekalert

Related medicine news :

1. New Genetic Clues to Breast Cancer?
2. Gladstone scientists identify genetic mechanism linked to congenital heart disease
3. Newborn screening program aims to help transform treatments for genetic diseases detected at birth
4. A genetic accelerator hits the gas on autoimmune diseases
5. UNC scientists collaborate to find first major genetic mutation associated with hereditary prostate cancer risk
6. TGen researchers map potential genetic origins, pathways of lung cancer in nonsmokers
7. Genetic predisposition to disease common in 2 supercentenarians: New study
8. Doubt Cast on Use of Genetic Test Before Plavix
9. Analysis does not support genetic test before use of anti-clotting drug
10. Key genetic error found in family of blood cancers
11. Researchers describe a new genetic program that converts static cells into mobile invasive cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... for contaminated soil, dredged material, and hazardous and non-hazardous materials announced today the ... Pennsylvania. This acquisition will add four additional processing facilities and a vast ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions ... the United States, it’s a threat that is constantly changing and evolving. Mediaplanet's ... and offers strategies for the healthcare community to help decrease the number of ...
(Date:3/24/2017)... ... 24, 2017 , ... According to a new study by NCPA Senior Fellow ... obey the rules Congress has directed the CBO to follow. The CBO itself previously ... restore. Yet, it estimates a reduction in employer-based coverage due to the GOP reform, ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mlynarek Insurance ... to families and business owners across eastern Michigan, is connecting with the Oxford/Orion ... with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ensure homeless, ...
(Date:3/24/2017)... ... 24, 2017 , ... As the standards bearer of advanced ... that positions them as the go-to thought leader in all matters concerning oncology ... an always-on, always-fresh news, views and advocacy engine, called ONS Voice. , The ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017 New England Pediatric ... of an award including funding and in-kind service towards ... technology.  "Making blood draws less traumatic ... their whole hospital experience better.  We,re looking forward to ... can help improve care for the kids we treat," ...
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
Breaking Medicine Technology: